CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S81
DOI: 10.1055/s-0039-1686057
Abstracts
Oncology

Genetic Alterations in HPV-associated Oropharyngeal Squamous Cell Carcinoma of Patients with Treatment Failure

H Reder
1   HNO-Heilkunde, Kopf-Halschirurgie, Gießen
,
S Wagner
2   Kopf-Hals-Tumorforschung, HNO-Heilkunde, JLU Gießen, Gießen
,
U Gamerdinger
3   Institut für Pathologie, Universitätsklinikum Gießen, Gießen
,
S Sandmann
4   Institut für Medizinische Informatik, Westfäliche-Wilhems Universität Münster, Münster
,
N Würdemann
5   HNO-Heilkunde, Universitätklinikum Köln, Köln
,
A Bräuninger
3   Institut für Pathologie, Universitätsklinikum Gießen, Gießen
,
M Dugas
4   Institut für Medizinische Informatik, Westfäliche-Wilhems Universität Münster, Münster
,
S Gattenlöhner
3   Institut für Pathologie, Universitätsklinikum Gießen, Gießen
,
JP Klußmann
5   HNO-Heilkunde, Universitätklinikum Köln, Köln
,
C Wittekindt
2   Kopf-Hals-Tumorforschung, HNO-Heilkunde, JLU Gießen, Gießen
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction:

    An increasing number of oropharyngeal squamous cell carcinoma (OPSCC) is associated with human papillomavirus (HPV). Despite different biological and clinical features HPV+ and HPV- OPSCC are treated equally. Due to improved survival rates compared to patients with HPV- OPSCC, de-escalating treatment strategies are discussed for patients with HPV+ OPSCC. However, a subgroup of patients with HPV+ OPSCC might not benefit from de-escalated treatment due to an increased risk of treatment failure. Therefore, we aimed to identify genetic alterations as potential biomarkers associated with a risk of treatment failure.

    Methods:

    Primary tumor tissue of 12 patients with HPV+ OPSCC and severe course (SC) and best-matching pairs with a favorable course (FC) of disease was analyzed by targeted next generation sequencing and a SNP array for genetic and chromosomal aberrations.

    Results:

    No significant differences were observed between SC and FC patients on a chromosomal level. However, on the selected gene panel SC patients had more mutations than FC patients. Especially, STK11, HRAS, PIK3R1 and TP63 were strikingly more frequently altered in SC patients than in FC patients. Additionally, the combination of mutations and chromosomal aberrations on chromosomes 16 and 19 might influence outcome.

    Conclusion:

    Compared to SC patients FC patients had a higher number of genetic mutations in the genes studied. Our research shows that genetic markers could be used to identify patients at risk for treatment failure.


    #
    M.Sc. Henrike Reder
    HNO-Heilkunde, Kopf-Halschirurgie,
    Aulweg 128, 35392
    Gießen

    Publication History

    Publication Date:
    23 April 2019 (online)

    © 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York